Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism · 22.04.2025 · 110 (5) · 1205-1217
DOI: 10.1210/clinem/dgaf011 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.01.2025. Verfasst von Dalal S Ali und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada L8S 4L8. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: McMaster University.
Abstract (Originalsprache)
Objective
To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations.
Methods
We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals younger than 18 years with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to either no treatment or conventional therapy (phosphate and active vitamin D) or evaluating conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty.
Results
We screened 4114 records and assessed 254 full texts. One RCT and one post hoc study proved eligible when comparing burosumab to conventional therapy or no treatment. The open-label RCT was at high RoB, with certainty of evidence ranging from moderate to very low. Burosumab, compared to conventional therapy, probably prevents lower limb deformity and improves physical health quality of life (QoL) (moderate certainty). Burosumab may increase height and enhance the burden of symptoms related to chronic hypophosphatemia (low certainty). Burosumab probably increases treatment-emergent adverse events (moderate certainty) and may increase dental abscesses (low certainty). One observational study assessing conventional therapy vs no treatment was at high RoB, providing very low certainty evidence regarding the impact of conventional therapy on final height.
Conclusion
Our review indicates that burosumab likely provides benefits to children by preventing lower limb deformity and improving physical health QoL while potentially increasing height. However, burosumab may also increase adverse events. Our review found limited evidence regarding the impact of conventional therapy compared to no treatment on final height. Further research is required to understand the long-term effect of medical therapy in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada L8S 4L8.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada L8S 4L8.
- Department of Pediatrics, Faculty of Medicine & Dentistry, The University of Alberta, Edmonton, AB, Canada T6G 2R3.
- Department of Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center, 2300 ZA Leiden, the Netherlands.
- Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Université Paris Cité, 75006 Paris, France.
- Institut Imagine, INSERM 1163, 75015 Paris, France.
ORCID-Profile: Dalal S Ali, Reza D Mirza, Salma Hussein, Farah Alsarraf, R Todd Alexander, Hajar Abu Alrob, Natasha M Appelman-Dijkstra, Martin Biosse-Duplan, Maria Luisa Brandi, Thomas O Carpenter, Catherine Chaussain, Karel Dandurand, Guido Filler, Pablo Florenzano, Seiji Fukumoto, Corinna Grasemann, Erik A Imel, Suzanne M Jan de Beur, Emmett Morgante, Leanne M Ward, Aliya A Khan, Gordon Guyatt
Förderung
- McMaster University
Zitieren
APA
Ali, D. S., Mirza, R. D., Hussein, S., Alsarraf, F., Alexander, R. T., Abu Alrob, H., Appelman-Dijkstra, N. M., Biosse-Duplan, M., Brandi, M. L., Carpenter, T. O., Chaussain, C., Dandurand, K., Filler, G., Florenzano, P., Fukumoto, S., Grasemann, C., Imel, E. A., Jan de Beur, S. M., Morgante, E., …, & Guyatt, G. (2025). Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism, 110(5), 1205-1217. https://doi.org/10.1210/clinem/dgaf011
Vancouver
Ali DS, Mirza RD, Hussein S, Alsarraf F, Alexander RT, Abu Alrob H, et al. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 2025;110(5):1205-1217. doi:10.1210/clinem/dgaf011
BibTeX
@article{Ali2025,
author = {Ali, Dalal S and Mirza, Reza D and Hussein, Salma and Alsarraf, Farah and Alexander, R Todd and Abu Alrob, Hajar and Appelman-Dijkstra, Natasha M and Biosse-Duplan, Martin and Brandi, Maria Luisa and Carpenter, Thomas O and Chaussain, Catherine and Dandurand, Karel and Filler, Guido and Florenzano, Pablo and Fukumoto, Seiji and Grasemann, Corinna and Imel, Erik A and Jan de Beur, Suzanne M and Morgante, Emmett and Ward, Leanne M and Khan, Aliya A and Guyatt, Gordon},
title = {Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {5},
pages = {1205--1217},
doi = {10.1210/clinem/dgaf011}
}
EUVIMED